A new application of Dengyinnaotong composition

Abstract

The present invention belongs to the field of traditional Chinese medicine and discloses a new use of a Dengyinnaotong composition. The Dengyinnaotong composition includes Dengzhan Xixin, Ginkgo Biloba, Panax Notoginseng, and Rhizoma Cimicifugae. The application of the Dengyinnaotong composition in the preparation of a medicament for preventing and / or treating atherosclerosis has the effect of significantly inhibiting atherosclerotic plaques and regulating blood lipids. At the same time, the Dengyinnaotong composition has a protective effect on ileal tissue and / or colon tissue, can significantly increase the average number of goblet cells per villus of the ileum, the length of the villi, and the thickness of the muscular layer, and can increase the number of goblet cells per crypt of the colon tissue. The application of the Dengyinnaotong composition in the preparation of a medicament for regulating intestinal flora can significantly increase the abundance of Alloprevotella_Bacteroides, Ruminococcus, Prevotellaceae_NK3B31_group, and Parabacteroides at the genus level, and significantly reduce the abundance of Blautia and Desulfovibrio. The new use of the Dengyinnaotong composition found in the present invention has expanded the scope of clinical application of the Dengyinnaotong composition and has broad application prospects.

Description

Technical Field

[0001] The invention belongs to the field of traditional Chinese medicine, and in particular relates to a new use of a Dengyinnaotong composition. Background Art

[0002] The incidence and mortality rates of cardiovascular diseases have consistently ranked first globally, with an increasing trend year by year. Atherosclerosis is a major contributing factor to cardiovascular disease, primarily affecting large and medium-sized arteries. It is often caused by metabolic disorders of fat and neurovascular dysfunction, manifesting as intimal thickening, the appearance of foam cells, and the formation of atherosclerotic plaques. Plaques intrude into the arterial lumen, causing vascular stenosis. Rupture of the plaques leads to secondary atherothrombosis, triggering serious clinical cardiovascular and cerebrovascular events. Atherosclerosis is the primary pathological basis and key link in the development of cardiovascular disease, and the formation and shedding of plaques on the vessel wall are the primary factors in severe cardiovascular events. Therefore, the prevention and treatment of atherosclerosis has become a major task in today's world.

[0003] Atherosclerosis is a complex, multifactorial disease whose specific pathogenesis remains unclear. However, studies suggest that the gut microbiome plays a significant role in the development and progression of atherosclerosis. The intestine is the body's largest endocrine neurohormonal network, and the gut microbiome plays a key role in maintaining homeostasis. The gut microbiome promotes many essential and beneficial physiological processes, such as the digestion of numerous nutrients and the synthesis of some vitamins. At the same time, considerable evidence suggests that the gut microbiome plays a role in the development of adverse phenotypes. In particular, significant changes in the structure and function of the microbiome are associated with various disease states. Studies have found that the composition and structure of the gut microbiome in patients with coronary atherosclerosis differ significantly from that in healthy controls. Patients with coronary atherosclerosis exhibit significantly increased abundance of three microbial clusters, represented by Enterobacteriaceae, oral bacteria (such as Streptococcus), and Clostridium. This increase in microbial abundance significantly suppresses the enrichment of beneficial bacteria, such as Clostridium tenella. Importantly, earlier sequencing studies by researchers have revealed the presence of bacterial DNA in human atherosclerotic plaques, likely originating from the gut or oral cavity.

[0004] The intestinal microbial barrier is composed of healthy intestinal flora. In a healthy state, the intestinal barrier function is maintained by physical factors, including tight junctions between epithelial cells, mucus production, and mucosal immunity. When the intestinal flora is imbalanced, the expression of tight junction proteins is inhibited, thereby increasing intestinal permeability. According to the concept of intestinal leakage, impaired intestinal barrier function causes bacterial products to enter the host circulation, leading to a pro-inflammatory state. Studies have shown that ApoE in atherosclerosis models - / -Impaired intestinal barrier function in mice exacerbates the progression of atherosclerosis. In response to a high-fat diet, the gut microbiota produces endotoxins, which induce vascular inflammation and metabolic disorders through CD14. Endotoxins also engage toll-like receptor-4 and activate signaling pathways, leading to the expression of inflammatory cytokines.

[0005] Dengyinnaotong pharmaceutical composition, such as Dengyinnaotong capsule, is a traditional Chinese medicine compound preparation composed of four Chinese medicinal materials: Dengzhan Xixin, Ginkgo Biloba, Panax Notoginseng, and Rhizoma Cibotii. It is a clinical medicine used to treat meridian and blood stasis syndrome in stroke, and has the effects of promoting qi and blood circulation, dispersing blood stasis and unblocking meridians.

[0006] At present, the Dengyin Naotong pharmaceutical composition is mostly used in the treatment of cerebral stroke and has a certain clinical application basis, but there is no literature reporting whether the Dengyin Naotong pharmaceutical composition has an intervention effect on atherosclerosis, nor is there any literature reporting whether the Dengyin Naotong pharmaceutical composition can regulate intestinal flora or protect ileum tissue and / or colon tissue.

[0007] In view of this, the present invention is proposed. Summary of the Invention

[0008] The technical problem to be solved by the present invention is to overcome the deficiencies of the prior art and provide a new use of a Dengyinnaotong composition. The present invention finds that the Dengyinnaotong composition has the effect of inhibiting atherosclerosis, regulating intestinal flora, and protecting ileal tissue and / or colon tissue.

[0009] In order to solve the above technical problems, the basic concept of the technical solution adopted by the present invention is:

[0010] The first object of the present invention is to provide a use of a Dengyinnaotong composition in the preparation of a medicament for preventing and / or treating atherosclerosis.

[0011] Dengyinnaotong (Dengyinnaotong) capsules, developed based on the Dengyinnaotong (Dengyinnaotong) composition, are listed in the National Drug Standard WS-10843 (ZD-0843)-2002-2012Z and are currently used primarily to treat stroke. Atherosclerosis is a condition characterized by both underlying deficiency and superficial excess, with visceral qi deficiency as the underlying condition and phlegm, blood stasis, and toxins as the superficial symptoms. These deficiency, phlegm, blood stasis, and toxins often play a causal role, leading to a comprehensive clinical approach that combines phlegm-resolving and lipid-lowering, blood circulation-activating and blood stasis-removing, heat-clearing and toxic-removing, and qi-invigorating and yin-nourishing properties.

[0012] The present invention has found through experiments that the Dengyinnaotong composition has an inhibitory and intervention effect on atherosclerosis and can be used to prepare a drug for preventing and / or treating atherosclerosis.

[0013] A further solution is the use of the Dengyinnaotong composition in the preparation of a drug for inhibiting atherosclerotic plaques.

[0014] A further solution is the use of the Dengyinnaotong composition in the preparation of a drug for regulating blood lipid levels in atherosclerosis.

[0015] The second object of the present invention is to provide the use of the Dengyinnaotong composition in the preparation of a medicament for protecting ileal tissue and / or colon tissue.

[0016] In a further embodiment, the ileum tissue is ileum tissue with atherosclerosis, and protecting the ileum tissue with atherosclerosis includes increasing the average number of goblet cells per villus of the ileum, increasing the length of the villi, and increasing the thickness of the muscular layer.

[0017] In a further embodiment, the colon tissue is atherosclerotic colon tissue, and protecting atherosclerotic colon tissue includes increasing the number of goblet cells in each crypt of the colon tissue.

[0018] A further solution is the use of the Dengyinnaotong composition in the preparation of a drug for regulating intestinal flora in atherosclerosis;

[0019] Preferably, the Dengyinnaotong composition increases the abundance of intestinal probiotics and reduces the abundance of harmful bacteria;

[0020] Preferably, the Dengyinnaotong composition increases the abundance of Alloprevotella, Bacteroides, Ruminococcus, Prevotellaceae_NK3B31_group and Parabacteroides genera, and reduces the abundance of Blautia and Desulfovibrio genera.

[0021] The second object of the present invention is to provide an application of a Dengyinnaotong composition in the preparation of a drug for regulating intestinal flora.

[0022] A further solution is the use of the Dengyinnaotong composition in the preparation of a drug for regulating intestinal flora to intervene in atherosclerosis.

[0023] In a further embodiment, the Dengyinnaotong composition increases the abundance of Alloprevotella, Bacteroides, Ruminococcus, Prevotellaceae_NK3B31_group and Parabacteroides genera, and the Dengyinnaotong composition reduces the abundance of Blautia and Desulfovibrio genera.

[0024] In a further embodiment, the Dengyinnaotong composition is composed of Erigeron breviscapus, Ginkgo biloba, Panax notoginseng, and Rhizoma Cyperi;

[0025] In a further embodiment, the Dengyinnaotong composition comprises: 300-600 parts by weight of Erigeron breviscapus, 300-600 parts by weight of Rhizoma Cyperi, 300-600 parts by weight of Ginkgo biloba leaves, and 100-300 parts by weight of Panax notoginseng;

[0026] Preferably, the Dengyinnaotong composition comprises: 400-550 parts by weight of Erigeron breviscapus, 400-550 parts by weight of Rhizoma Cyperi, 400-550 parts by weight of Ginkgo biloba leaves, and 150-250 parts by weight of Panax notoginseng;

[0027] More preferably, the Dengyinnaotong composition comprises: 500 parts by weight of Erigeron breviscapus, 500 parts by weight of Rhizoma Cyperi, 500 parts by weight of Ginkgo biloba leaves, and 200 parts by weight of Panax notoginseng.

[0028] Preferably, the Dengyinnaotong composition further comprises pharmaceutically acceptable excipients;

[0029] Preferably, the dosage form of the Dengyinnaotong composition is selected from capsules, tablets, injections, powders, pills, granules or oral liquids.

[0030] Preferably, the Dengyinnaotong composition is Dengyinnaotong capsule, and more preferably, the approval number of the Dengyinnaotong capsule is: National Medicine Standard Z20026228. After adopting the above technical solution, the present invention has the following beneficial effects compared with the prior art:

[0031] 1. The present invention found that the Dengyinnaotong composition has an inhibitory intervention effect on atherosclerosis, specifically:

[0032] (1) The Dengyinnaotong composition has a significant effect of inhibiting atherosclerotic plaques;

[0033] (2) The Dengyinnaotong composition has the effect of regulating the blood lipid levels of atherosclerotic mice;

[0034] 2. The Dengyinnaotong composition has a protective effect on ileum tissue and colon tissue.

[0035] The Dengyinnaotong combination also has a significant protective effect on the ileum tissue of mice with atherosclerosis, and can significantly increase the average number of goblet cells per villus in the ileum, the villus length and the muscle layer thickness.

[0036] The Dengyinnaotong composition has a certain protective effect on the colon tissue of atherosclerotic mice and can increase the number of goblet cells in each crypt of the colon tissue.

[0037] 3. The Dengyin Naotong combination has a regulatory effect on intestinal flora. Specifically, 16S rDNA sequencing analysis revealed that Dengyin Naotong capsules significantly increased the abundance of beneficial bacteria. At the genus level, it significantly increased the abundance of Alloprevotella_Bacteroides, Ruminococcus, Prevotellaceae_NK3B31_group, and Parabacteroides, while significantly reducing the abundance of harmful bacteria: Blautia and Desulfovibrio. The Dengyin Naotong combination has a regulatory effect on the intestinal flora associated with atherosclerosis.

[0038] The new use of the Dengyinnaotong composition discovered by the present invention expands the scope of clinical application of the Dengyinnaotong composition (such as Dengyinnaotong capsule) and has broad application prospects.

[0039] The specific embodiments of the present invention will be described in further detail below with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] The accompanying drawings are part of the present invention and are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention, but do not constitute an undue limitation of the present invention. Obviously, the drawings described below are only some embodiments. For those of ordinary skill in the art, other drawings can be obtained based on these drawings without inventive effort. In the accompanying drawings:

[0041] Figure 1 A is the gross staining of mouse aorta with Oil Red O; B is the statistics of the gross staining plaque area of ​​mouse aorta; C is the HE staining of mouse aortic root; D is the Oil Red O staining of mouse aortic root; E is the Masson's trichrome staining of mouse aortic root; F is the statistics of the proportion of plaque and necrotic core in mouse aortic root; G is the statistics of the proportion of lipid deposition and plaque fibrosis in mouse aortic root (Note: **P < 0.01; *P < 0.05);

[0042] Figure 2 is the serum lipid level of mice in each group (Note: **P<0.01; *P<0.05);

[0043] Figure 3 A is H&E staining of ileum tissue; B is Alcian blue staining of ileum tissue; C is the average number of goblet cells per ileal villus, the average length of ileal villi, and the average muscularis thickness (Note: *P < 0.05; **P < 0.01; ****P < 0.0001; nsP > 0.05);

[0044] Figure 4A is H&E staining of colon tissue; B is Alcian blue staining of colon tissue; C is the average number of goblet cells in each crypt, the average crypt depth of the colon, and the average muscular thickness of the colon (Note: nS P > 0.05);

[0045] Figure 5 A is the Chao1 index; B is the PCoA principal component analysis; C is the relative abundance of each group at the phylum level; D is the relative abundance of each group at the genus level; E is the species with significant differences at the genus level (Note: *P < 0.05; **P < 0.01).

[0046] It should be noted that these drawings and textual descriptions are not intended to limit the conceptual scope of the present invention in any way, but rather to illustrate the concept of the present invention for those skilled in the art by referring to specific embodiments. DETAILED DESCRIPTION

[0047] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. The following embodiments are used to illustrate the present invention but are not used to limit the scope of the present invention.

[0048] It should be noted that the Dengyinnaotong composition described in the present invention includes any Chinese medicine compound preparation composed of four Chinese medicinal materials: Erigeron breviscapus, Ginkgo biloba, Panax notoginseng, and Rhizoma Cynanchum. The dosage form is not limited to capsules, tablets, or other dosage forms. In the present invention, Dengyinnaotong capsules were specifically used for testing.

[0049] 1. Dengyinnaotong Composition (Dengyinnaotong Capsule)

[0050] Prescription: 500g of Erigeron chinensis, 500g of Rhizoma Cyperi, 500g of Ginkgo biloba leaves, and 200g of Panax notoginseng.

[0051] Preparation method: Soak the above four ingredients in water for 4 hours, decoct three times, each time for 2 hours, combine the decoctions, filter, add ethanol to the filtrate to make the alcohol content reach 70%, mix well, let it stand for 24 hours, filter, recover ethanol from the filtrate until there is no alcohol taste, dry under reduced pressure, grind into powder, add 100g starch, 30g microcrystalline cellulose, 3g polysorbate 80, 0.5g hydroxypropyl methylcellulose, 2g magnesium stearate, and 17.5g sodium carboxymethyl cellulose, granulate, put into capsules, and make 1000 capsules.

[0052] The Dengyinnaotong capsules used in the following experiments of the present invention are produced by Kunming Pharmaceutical Group Co., Ltd.

[0053] 2. Experimental Methods

[0054] 1. Experimental Animals

[0055] Twenty-seven 8-week-old SPF-grade ApoE- / - mice and eight C57 mice (half male and half female) were obtained from Shanghai Slake Animal Co., Ltd. They were housed at the Animal Experimental Center of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, affiliated with Shanghai University of Traditional Chinese Medicine. The temperature was maintained at 25 ± 2°C; the humidity was 40%-55%; and the photoperiod was 12 h light / 12 h dark. All procedures were in accordance with the ethical guidelines of the Experimental Animal Care Committee of Shanghai University of Traditional Chinese Medicine (18867).

[0056] After one week of adaptive feeding with free access to water and food, 27 ApoE- / - mice were randomly divided into three groups: a high-fat diet (0.5% CMCNA, HFD) group, a low-dose Dengyinnaotong group (0.2g / kg / d, dissolved in 0.5% CMCNA (0.5% sodium carboxymethylcellulose aqueous solution), designated DYNT-L), and a high-dose Dengyinnaotong group (1g / kg / d, dissolved in 0.5% CMCNA, designated DYNT-H). C57 mice served as a normal control group. The drug groups were gavaged with 200ul of Dengyinnaotong capsules at different concentrations, while the normal control and high-fat diet groups were given an equal volume of 0.5% CMCNA for 8 consecutive weeks.

[0057] 2. Animal Handling

[0058] After the last drug intervention, feces of mice in each group were collected by abdominal massage and frozen in a -80°C freezer. The next day, all animals were sacrificed after orbital blood collection. The mice were fixed and the hearts were exposed. 0.9% saline was perfused at the apex of the heart until clear fluid flowed out. The heart and thoracic aorta were removed together. The distal ileum and proximal colon of each group of mice were longitudinally dissected and divided into two. Half of the mice in each group were randomly selected to keep the aorta and ileum, and stored in a -80°C freezer for subsequent expression analysis; the aorta and ileum of the remaining half of the mice in each group were fixed with 4% paraformaldehyde, embedded in paraffin, and subjected to histopathological analysis.

[0059] 3. Histomorphological Analysis

[0060] All samples were sliced ​​into 4 μm sections.

[0061] Observation of pathological changes in aorta and intestinal tissues by aH&E staining

[0062] b. Masson's trichrome staining to observe the severity of collagen deposition to reflect the degree of aortic fibrosis

[0063] c. Oil red O staining to observe lipid deposition in aortic plaques

[0064] d. Alcian blue staining to observe the changes in the number of goblet cells in intestinal tissue

[0065] 4. Serum Biochemical Analysis

[0066] The mouse blood was centrifuged at 3000 rpm for 10 min to extract serum, and the biochemical indicators TC, TG, LDL-C, and HDL-C in the serum were detected using the biochemical kit of Nanjing Jiancheng Bioengineering Institute.

[0067] 5. Fecal 16S rDNA Sequencing

[0068] Fresh fecal DNA was extracted using the QIAamp Fast DNA Stool Mini Kit, amplified by PCR, and sequenced for 16S rDNA using the MiSeq system (Illumina, USA). Sequencing was performed by Shanghai Ouyi Biomedical Technology Co., Ltd.

[0069] 3. Experimental Results

[0070] 1. Dengyinnaotong Capsule has a significant effect in inhibiting atherosclerotic plaques

[0071] like Figure 1 As shown in A, the results of macroscopic Oil Red O staining of the aorta showed that the high-dose group of Dengyinnaotong Capsule could significantly inhibit the formation of plaques in the aortic arch and thoracic aorta (P < 0.05). Figure 1 C), indicating that all three groups of mice had obvious plaques in the aortic root. Compared with the HFD group, the high-dose Dengyinnaotong capsule group could significantly reduce the size of atherosclerotic plaques (P < 0.05). At the same time, the high-dose Dengyinnaotong capsule group could significantly reduce the size of the necrotic core in the plaque. Figure 1 As shown in D, Oil Red O staining of the aortic root of mice showed that the aortic root plaques of the three groups of mice had different degrees of lipid deposition, and compared with the HFD group, the high-dose Dengyinnaotong Capsule group could significantly reduce the lipid deposition in the plaques (P < 0.05). Figure 1 As shown in E, Masson's trichrome staining of the aortic root of mice showed varying degrees of fibrosis in the aortic root plaques of the three groups of mice, and compared with the HFD group, the low-dose and high-dose Dengyinnaotong capsule groups could reduce the level of plaque fibrosis to a certain extent.

[0072] 2. Dengyinnaotong Capsule has the effect of regulating blood lipid levels in mice with atherosclerosis

[0073] like Figure 2As shown, the serum LDL-C, HDL-C, TC, and TG levels of each group of mice were measured. Compared with the C57 group, the HFD group had significantly increased LDL-C, TC, and TG levels (P < 0.05), while the HDL-C level was significantly decreased (P < 0.05). Compared with the HFD group, the high-dose Dengyinnaotong Capsule group significantly reduced the TC and TG levels (P < 0.05) and significantly increased the HDL-C level (P < 0.05), but had no effect on LDL-C.

[0074] 3. Dengyinnaotong Capsule has a significant protective effect on the ileum tissue of mice with atherosclerosis

[0075] H&E and Alcian blue staining of ileum tissues showed that the pathological results showed that villi were lost in some areas of the ileum tissue of mice in the HFD group, local tissue edema and inflammatory cell infiltration; while the ileum pathological damage in the low-dose and high-dose Dengyinnaotong capsule groups was alleviated to varying degrees compared with the HFD group ( Figure 3 A). The average number of goblet cells per villus, villus length, and muscularis thickness in ileum tissue were quantified and statistically analyzed. The results showed that compared with the HFD group, the Dengyinnaotong capsule group significantly increased the average number of goblet cells per villus, villus length, and muscularis thickness ( Figure 3 BC), and the effect of the high-dose Dengyinnaotong group was more significant (P<0.05).

[0076] 4. Dengyinnaotong Capsule has a certain protective effect on the colon tissue of atherosclerotic mice

[0077] H&E staining of colon tissue was performed. Figure 4 As shown in A, mucosal and muscularis damage were observed in the colon tissue of mice fed a high-flow diet (HFD). Both the low- and high-dose Dengyinnaotong groups alleviated pathological damage to colonic tissue to a certain extent, with the high-dose group showing a more pronounced effect. The number of goblet cells per crypt, crypt depth, and muscularis thickness in colonic tissue were quantified. The results suggest that the high-dose Dengyinnaotong group increased the number of goblet cells per crypt to a certain extent compared to the HFD group.

[0078] 5. Dengyinnaotong Capsule has the effect of regulating intestinal flora

[0079] By 16s rDNA sequencing analysis, Figure 5 As shown in A, Chao1 is the species richness index, indicating that the bacterial abundance in the Dengyinnaotong capsule treatment group was significantly higher than that in the HFD group. Figure 5The results of principal component analysis B showed that there were significant differences in the microbial flora between the high-dose Yinnaotong capsule group and the HFD group. By comparing the changes in the abundance of the microbial flora at the phylum and genus levels among the groups, the results showed that there were no significant differences in the microbial flora at the phylum level, but there were significant differences at the genus level (P < 0.05). Yinnaotong capsule significantly increased the abundance of Alloprevotella, Bacteroides, Ruminococcus, Prevotellaceae_NK3B31_group and Parabacteroides, and significantly reduced the abundance of Blautia and Desulfovibrio ( Figure 5 CE).

[0080] Summarize

[0081] Dengyinnaotong Capsule significantly inhibited the formation of atherosclerotic plaques in ApoE- / - mice, modulated blood lipids, and significantly improved ileal pathological lesions, significantly increasing the average number of goblet cells per villus, villus length, and muscularis thickness. 16S rDNA sequencing analysis revealed that Dengyinnaotong Capsule significantly increased bacterial abundance. At the genus level, it significantly increased the abundance of Alloprevotella, Bacteroides, Ruminococcus, Prevotellaceae_NK3B31_group, and Parabacteroides, while significantly decreasing the abundance of Blautia and Desulfovibrio.

[0082] The above description is merely a preferred embodiment of the present invention and does not constitute any form of limitation to the present invention. Although the present invention has been disclosed as above in terms of a preferred embodiment, it is not intended to limit the present invention. Any technician familiar with the present invention can make slight changes or modifications to equivalent embodiments using the above-mentioned technical contents without departing from the scope of the technical solution of the present invention. However, any simple modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the solution of the present invention.

Claims

1. Use of a Dengyinnaotong composition in the preparation of a medicament for protecting ileal tissue and / or colon tissue.

2. The use according to claim 1, characterized in that The ileal tissue is atherosclerotic ileal tissue.

3. The use according to claim 1, characterized in that The application includes increasing the average number of goblet cells per villus of the ileum, increasing the length of the villi, and increasing the thickness of the muscular layer.

4. The use according to claim 1, characterized in that The colon tissue is atherosclerotic colon tissue.

5. The use according to claim 1, characterized in that The application includes increasing the number of goblet cells per crypt in colon tissue.

6. The use according to any one of claims 1 to 5, characterized in that The Dengyinnaotong composition consists of Erigeron breviscapus, Ginkgo biloba leaves, Panax notoginseng and Rhizoma Cyperi.

7. The use according to claim 6, characterized in that The Dengyinnaotong composition further comprises pharmaceutically acceptable excipients.

8. The use according to claim 6, characterized in that The dosage form of the Dengyinnaotong composition is selected from capsules, tablets, injections, powders, pills, granules or oral liquids.

9. The use according to claim 6, characterized in that The Dengyinnaotong composition is Dengyinnaotong capsule.

10. Use of a Dengyinnaotong composition in the preparation of a drug for regulating intestinal flora in atherosclerosis.

11. The use according to claim 10, characterized in that The Dengyinnaotong composition increases the abundance of intestinal probiotics and reduces the abundance of harmful bacteria.

12. The use according to claim 11, characterized in that The Dengyinnaotong composition increased the abundance of Alloprevotella, Bacteroides, Ruminococcus, Prevotellaceae_NK3B31_group and Parabacteroides genera, and reduced the abundance of Blautia and Desulfovibrio genera.

13. The use according to any one of claims 10 to 12, characterized in that: The Dengyinnaotong composition consists of Erigeron breviscapus, Ginkgo biloba leaves, Panax notoginseng and Rhizoma Cyperi.

14. The use according to claim 13, characterized in that The Dengyinnaotong composition further comprises pharmaceutically acceptable excipients.

15. The use according to claim 13, characterized in that The dosage form of the Dengyinnaotong composition is selected from capsules, tablets, injections, powders, pills, granules or oral liquids.

16. The use according to claim 13, characterized in that The Dengyinnaotong composition is Dengyinnaotong capsule.

17. Use of a Dengyinnaotong composition in the preparation of a drug for regulating intestinal flora.

18. The use according to claim 17, characterized in that Application of the Dengyinnaotong composition in the preparation of a medicine for regulating intestinal flora and intervening in atherosclerosis.

19. The use according to claim 17, characterized in that The Dengyinnaotong composition increased the abundance of Alloprevotella, Bacteroides, Ruminococcus, Prevotellaceae_NK3B31_group and Parabacteroides genera, and reduced the abundance of Blautia and Desulfovibrio genera.

20. The use according to any one of claims 17 to 19, characterized in that: The Dengyinnaotong composition consists of Erigeron breviscapus, Ginkgo biloba leaves, Panax notoginseng and Rhizoma Cyperi.

21. The use according to claim 20, characterized in that The Dengyinnaotong composition further comprises pharmaceutically acceptable excipients.

22. The use according to claim 20, characterized in that The dosage form of the Dengyinnaotong composition is selected from capsules, tablets, injections, powders, pills, granules or oral liquids.

23. The use according to claim 20, characterized in that The Dengyinnaotong composition is Dengyinnaotong capsule.

Images